Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Sell
15
KRRO Quote, Financials, Valuation and Earnings
Last price:
$43.19
Seasonality move
:
-23.5%
Day range:
$42.58 - $44.90
52-week range:
$30.01 - $98.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.26x
Volume:
33K
Avg. volume:
129.4K
1-year change:
-14.29%
Market cap:
$405.6M
Revenue:
--
EPS (TTM):
-$10.30
Analysts' Opinion
-
Consensus RatingKorro Bio has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $137.76, Korro Bio has an estimated upside of 218.22% from its current price of $43.29.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $105.00 representing 100% downside risk from its current price of $43.29.
Fair Value
-
According to the consensus of 3 analysts, Korro Bio has 218.22% upside to fair value with a price target of $137.76 per share.
KRRO vs. S&P 500
-
Over the past 5 trading days, Korro Bio has underperformed the S&P 500 by -11.65% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Korro Bio does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Korro Bio has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Korro Bio reported revenues of --.
Earnings Growth
-
Korro Bio has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Korro Bio reported earnings per share of -$2.26.
Enterprise value:
268.6M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-2.93x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -$95.8M | -$19.1M | -$23.3M | |
| EBITDA | -- | -- | -$92.5M | -$18.2M | -$22.4M | |
| Diluted EPS | -- | -- | -$10.30 | -$2.31 | -$2.26 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | $49.1M | $152.8M | |
| Total Assets | -- | -- | -- | $95.8M | $243.5M | |
| Current Liabilities | -- | -- | -- | $9.5M | $13.6M | |
| Total Liabilities | -- | -- | -- | $249.1M | $63.9M | |
| Total Equity | -- | -- | -- | -$153.3M | $179.6M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -$73.7M | -$11.8M | -$16.1M | |
| Cash From Investing | -- | -- | -$122.2M | $754K | -$12.6M | |
| Cash From Financing | -- | -- | $213M | -$2.2M | $728K | |
| Free Cash Flow | -- | -- | -$91.8M | -$12M | -$21M | |
KRRO
Sector
Market Cap
$405.6M
$45.6M
Price % of 52-Week High
44.17%
45.55%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-14.29%
-31.35%
Beta (5-Year)
1.975
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$45.57
200-day SMA
Sell
Level
$51.05
Bollinger Bands (100)
Sell
Level
35.44 - 59.5
Chaikin Money Flow
Sell
Level
-26.8M
20-day SMA
Sell
Level
$47.05
Relative Strength Index (RSI14)
Sell
Level
42.55
ADX Line
Sell
Level
18.47
Williams %R
Neutral
Level
-57.1898
50-day SMA
Sell
Level
$55.55
MACD (12, 26)
Sell
Level
-2.40
25-day Aroon Oscillator
Sell
Level
-24
On Balance Volume
Neutral
Level
74.6M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
Stock Forecast FAQ
In the current month, KRRO has received 3 Buy ratings 0 Hold ratings, and 0 Sell ratings. The KRRO average analyst price target in the past 3 months is $137.76.
-
Where Will Korro Bio Stock Be In 1 Year?
According to analysts, the consensus estimate is that Korro Bio share price will rise to $137.76 per share over the next 12 months.
-
What Do Analysts Say About Korro Bio?
Analysts are divided on their view about Korro Bio share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Korro Bio is a Sell and believe this share price will drop from its current level to $105.00.
-
What Is Korro Bio's Price Target?
The price target for Korro Bio over the next 1-year time period is forecast to be $137.76 according to 3 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is KRRO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Korro Bio is a Buy. 3 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of KRRO?
You can purchase shares of Korro Bio via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Korro Bio shares.
-
What Is The Korro Bio Share Price Today?
Korro Bio was last trading at $43.19 per share. This represents the most recent stock quote for Korro Bio. Yesterday, Korro Bio closed at $43.29 per share.
-
How To Buy Korro Bio Stock Online?
In order to purchase Korro Bio stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
73
PSIX alert for Dec 24
Power Solutions International [PSIX] is up 27.42% over the past day.
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is up 8.07% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is down 1.39% over the past day.
